Literature DB >> 6778383

In vitro evaluation of Ro 13-9904.

A M Hinkle, G P Bodey.   

Abstract

The in vitro activity of a new investigational cephalosporin, Ro 13-9904, was compared with those of four cephalosporins (cephalothin, cefamandole, cefoxitin, and moxalactam), five semisynthetic penicillins (mezlocillin, piperacillin, carbenicillin, ticarcillin, and azlocillin), and the aminoglycoside tobramycin. Ro 13-9904 inhibited 75% of all isolates of Enterobacteriaceae at a concentration of 6.25 micrograms/ml, including Enterobacter spp., Serratia marcescens, and indole-positive Proteus spp. Ro 13-9904 was only minimally active against Pseudomonas aeruginosa and enterococci. There was no significant change (greater than or equal to 2 dilutions) in drug activity when tested in various pH and media. A significant inoculum effect occurred when the size of the inoculum was increased from a concentration of 10(5) to 10(7) organisms per ml.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6778383      PMCID: PMC284051          DOI: 10.1128/AAC.18.4.574

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors:  C M Findell; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  Comparative in vitro activity of cephalosporins.

Authors:  D Stewart; G P Bodey
Journal:  J Antibiot (Tokyo)       Date:  1976-02       Impact factor: 2.649

3.  Piperacillin: in vitro evaluation.

Authors:  G P Bodey; B Le Blanc
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

4.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

5.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

6.  Hospital isolates of Serratia marcescens transferring ampicillin, carbenicillin, and gentamicin resistance to other gram-negative bacteria including Pseudomonas aeruginosa.

Authors:  V M Olexy; T J Bird; H G Grieble; S K Farrand
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

  6 in total
  22 in total

1.  Comparison of the serum bactericidal activity of ceftriaxone/piperacillin and ceftriaxone/netilmicin.

Authors:  K Machka; M Röbl; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

3.  In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers.

Authors:  M A Pfaller; A L Barry; L D Sabath; B N Kreiswirth; P R Murray; P C Fuchs; J C McLaughlin
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

Review 4.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

5.  Ceftriaxone: in vitro activity against 410 bacterial isolates compared with cefotaxime.

Authors:  A Digranes; E Benonisen; W L Dibb
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

6.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Ceftriaxone (Ro 13-9904) therapy of serious infection.

Authors:  R W Bradsher
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

8.  Ceftriaxone: in vitro studies and clinical evaluation.

Authors:  J W Gnann; W E Goetter; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Efficacy of ceftriaxone in serious bacterial infections.

Authors:  J S Epstein; S M Hasselquist; G L Simon
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections.

Authors:  M J Maslow; J F Levine; A A Pollock; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.